CRISPR patent battle continues

According to an article published in Nature, the U.S. Patent and Trademark Office (USPTO) has
ruled that the Broad Institute of Harvard and the Massachusetts Institute of Technology (MIT) in Cambridge, Mass., could keep its patents on using CRISPR–Cas9 in eukaryotic cells.